Recruiting

ConMed HelixAR™

Sponsor:

SurgiQuest, Inc.

Code:

NCT04165525

Conditions

Mastectomy; Lymphedema

Eligibility Criteria

Sex: Female

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Ablation

Study Details

Brief summary:

A PROSPECTIVE, RANDOMIZED, CONTROLLED STUDY TO EVALUATE DEVICE EFFICACY BETWEEN THE HELIXAR ELECTROSURGICAL GENERATOR (HEG) VS. CONVENTIONAL ELECTROSURGICAL COAGULATION (CEC) FOR CUTTING AND/OR COAGULATION OF TISSUE DURING MASTECTOMY PROCEDURES

Conditions

Mastectomy; Lymphedema

Study ID

NCT04165525

Start date

May 26, 2021

Status verified date

May, 2021

Completion date

Dec 30, 2022

Anticipated

Primary completion date

Jun 30, 2022

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. 18 to 80 years of age;
2. Capable and willing to give informed consent;
3. Acceptable candidate for a unilateral or bilateral mastectomy and reconstruction. All subjects enrolled and consented will undergo mastectomy with a breast reconstruction procedure, if it is in the subject's best interest.

Exclusion Criteria:

1. Advanced refusal of blood transfusion, if necessary;
2. Active systemic or cutaneous infection or inflammation;
3. Pre-existing immunodeficiency disorder and/or chronic use of systemic steroids;
4. Uncontrolled diabetes mellitus
5. Known, significant history of bleeding diathesis, or coagulopathy, or Von Willebrand's disease or current platelet count < 100,000 cells/mm3, or baseline INR ≥1.8, or fibrinogen level less than 150 mg/dl (if received a fibrinolytic agent within prior 24 hours);
6. Severe co-existing morbidities having a life expectancy of less than 30 days;
7. Currently involved in any other investigational clinical studies that could influence outcomes;
8. Significant anemia with a hemoglobin level less than 10 g/dL or a hematocrit less than 30%;
9. Renal insufficiency (serum creatinine of > 2.5 mg/dl);
10. Females who are pregnant, planning to become pregnant within 3 months of the procedure, or lactating;
11. Patients who have had previous partial mastectomies with scar tissue affecting the area to be resected.

Study Design

Enrollment

82 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: HelixAR Electrosurgical Generator (HEG)

Argon gas and high frequency electrical current ablation device

active comparator: Conventional Electrosurgical Coagulation (CEC) Systems

Standard Bovie electrosugical device without argon gas

Interventions

Ablation

comparison of using an argon gas and high frequency electrical current ablation device with a standard Bovie electrosugical device without argon gas.

Primary outcome measure

  • The time measured from post-mastectomy to hemostasis for each operated breast. [ Time Frame: Inter-operative ]

Central Contacts and Locations

Central contacts

Locations

Baylor St. Luke's Medical Center

Recruiting

Houston, Texas, United States, 77030

Contacts

More Information

Sponsor

SurgiQuest, Inc.

Last update posted

Jul 9, 2021

Last verified

May, 2021

Keywords

  • comparison of ablation devices

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by SurgiQuest, Inc. on 2021-07-09.